CAR-T for Solid Tumors: Q1 2026 Trial Readouts and the Off-the-Shelf Problem
CAR-T Solid Tumors: Q1 2026 Trial Readouts and the Off-the-Shelf Problem — For more than a decade, CAR-T cell therapy has been one of oncology’s most electrifying stories — and one of its most stubbornly partial ones. The technology can cure relapsed blood cancers that once carried months-long prognoses. It is less effective against the … Read more